Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 8,353 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Shannon Devers sold 8,353 shares of the business’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $75.95, for a total value of $634,410.35. Following the sale, the executive vice president owned 26,518 shares in the company, valued at approximately $2,014,042.10. The trade was a 23.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Ionis Pharmaceuticals Price Performance

Shares of IONS stock traded up $1.20 during trading hours on Tuesday, hitting $77.53. The company’s stock had a trading volume of 4,894,343 shares, compared to its average volume of 1,492,706. The company has a current ratio of 2.79, a quick ratio of 2.78 and a debt-to-equity ratio of 0.96. Ionis Pharmaceuticals, Inc. has a twelve month low of $23.95 and a twelve month high of $86.15. The business has a fifty day moving average of $78.90 and a 200-day moving average of $64.33. The stock has a market cap of $12.56 billion, a price-to-earnings ratio of -45.88 and a beta of 0.28.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings data on Wednesday, October 29th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.35. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 44.26%. The business had revenue of $156.72 million for the quarter, compared to analyst estimates of $131.75 million. During the same period in the prior year, the firm posted ($0.95) EPS. The company’s revenue was up 17.2% on a year-over-year basis. As a group, equities research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on IONS. Wells Fargo & Company upped their target price on Ionis Pharmaceuticals from $82.00 to $100.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Guggenheim lifted their price target on shares of Ionis Pharmaceuticals from $90.00 to $92.00 and gave the stock a “buy” rating in a research note on Tuesday, September 23rd. Stifel Nicolaus boosted their target price on shares of Ionis Pharmaceuticals from $43.00 to $67.00 and gave the stock a “hold” rating in a research report on Monday, October 6th. TD Cowen increased their price target on shares of Ionis Pharmaceuticals from $59.00 to $99.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Finally, JPMorgan Chase & Co. upgraded Ionis Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $49.00 to $80.00 in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $87.05.

More Ionis Pharmaceuticals News

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Analyst / media bullishness on olezarsen: A recent Seeking Alpha piece highlights an expected 2026 launch of olezarsen in SHTG and argues that approval/commercial rollout could drive a substantial revenue inflection for Ionis; the article notes strong recent momentum and positions olezarsen as the key upside catalyst. Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
• Neutral Sentiment: Trading and technicals: Intraday volume is elevated (~4.9M shares vs. a ~1.5M average), suggesting the market is actively reacting to the news flow; the stock is above its 200‑day moving average (support) but near the 50‑day average—momentum could depend on upcoming clinical/commercial milestones.
• Negative Sentiment: Large, concentrated insider selling: Multiple executives (including CEO Brett P. Monia and several EVPs) sold shares on Jan 16 totaling roughly 117K shares (~$8.8M) — CEO sale (~44K shares, ~$3.3M) and several EVP sales of ~8–13K shares each. These filings can be reviewed in the SEC disclosures, which may signal tax/diversification activity but can also weigh on sentiment.
  Bennett filing
  Birchler filing
  Devers filing
  Hougen filing
  Jenne filing
  Kordasiewicz filing
  Monia (CEO) filing
  O’neil filing
  Schneider filing
  Swayze filings

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. increased its holdings in shares of Ionis Pharmaceuticals by 72.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 652,518 shares of the company’s stock worth $19,686,000 after acquiring an additional 274,310 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Ionis Pharmaceuticals by 6.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 659,435 shares of the company’s stock worth $19,895,000 after buying an additional 39,794 shares in the last quarter. Focus Partners Wealth increased its position in Ionis Pharmaceuticals by 30.1% in the 1st quarter. Focus Partners Wealth now owns 9,832 shares of the company’s stock valued at $297,000 after acquiring an additional 2,277 shares during the period. Parallel Advisors LLC grew its position in Ionis Pharmaceuticals by 151.3% in the 2nd quarter. Parallel Advisors LLC now owns 1,872 shares of the company’s stock valued at $74,000 after buying an additional 1,127 shares in the last quarter. Finally, Wedmont Private Capital acquired a new position in Ionis Pharmaceuticals during the 2nd quarter valued at about $226,000. Institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.